

May 18, 2022

Perseus Proteomics, Inc.

Announcement of MOU Agreement on Joint Research on Super-neutralizing Antibody with University of Toyama and Toyama Prefecture

Perseus Proteomics Inc. (HQ: Tokyo, Japan; President & CEO: Takuya Yokokawa) is pleased to announce that the Company has signed a Memorandum of Understanding on joint research regarding COVID-19 “super-neutralizing antibody (development code: UT28K)” with University of Toyama and Toyama Prefecture (Department in charge: Department of Virology, Toyama Institute of Health and Toyama Pharmaceutical Valley Development Consortium Office).

COVID-19 has been continuously affecting daily life and economic activities globally through the new variants that have been arising one after another. In Japan, vaccination has been proceeding, however, the effectiveness of vaccine depends on the variant type or the period after vaccination. Although oral medical drugs have been developed, their effectiveness for unknown variants is still to be confirmed. Also, they are not prescribed for pregnant women as teratogenicity has been reported in animal experiments. Therefore, it is required to develop medical drugs that are undependable on mutation and able to cure patients safely and certainly against variants to emerge in the future.

Under such circumstances, the joint research group of Center for Advanced Antibody Drug Development and Institute of Natural Medicine, University of Toyama, Department of Virology, Toyama Institute of Health, Institute for Life and Medical Sciences, Kyoto University, and Faculty of Pharmaceutical Sciences, Hokkaido University has confirmed in the experiments that the human monoclonal antibody UT28K named “super-neutralizing antibody”, which University of Toyama obtained last year, has the potential to be a medical drug to prevent not only existing variants but also new variants of SARS-CoV-2 to arise in the future, as the press release of University of Toyama dated May 12, 2022.

The Company has been selected as a business partner of University of Toyama for speedy practical application of UT28K and has signed the MOU. Development of medical drugs of COVID-19 is, similarly to medical drugs for new pandemic, difficult to invest on due to various factors including constant emergence of new variants, difficulty of clinical development implementation affected by outbreak waves, and difficulty of estimating feasibility. On the other hand, the Company recognizes preparation of Japan-made medical drugs for COVID-19 new variants as a significantly important healthcare problem.

The Company will promote the development of the medical drug with University of Toyama and Toyama Prefecture through utilizing its experience of developing antibody medical drugs so far. According to the situation of government subsidy, acquisition, the Company has planned to proceed with the development for practical application step by step, from non-clinical studies, manufacture of GMP, safety studies among healthy volunteers through clinical study among patients. It will also aim at international medical contribution through the supply of UT28K not only to Japan but also to Asian nations where vaccination has been delayed. At the same time, it will promote practical application by establishing manufacture and stockpile systems for steady supply of domestic neutralizing antibody drugs to enable prompt response against new pandemics in the future.

[Other related information]

- [University of Toyama](#)
- [Toyama Pharmaceutical Valley Development Consortium](#)

[Contact]

Perseus Proteomics Inc.

Administrative Division Phone: +81-3-5738-1705 e-mail: ir@ppmx.com